Paediatric ganciclovir dosing in extracorporeal membrane oxygenation: Is standard dosing good enough?

Authors:

Abstract
What is known and objective Ganciclovir is a first‐line antiviral agent to treat cytomegalovirus disease in immunocomprimised patients. Ganciclovir pharmacokinetics in ECMO is unknown. Case description A 6‐year‐old with a stage IV extra‐renal rhabdoid tumor with respiratory failure leading to extracorporeal membrane oxygenation had increasing serum CMV DNAemia while on ganciclovir. What is new and conclusion This is the first case report of ganciclovir pharmacokinetics in either paediatric or adult ECMO populations. Recommended dosing provided a low, subtherapeutic AUC24 with an associated increase CMV viral load. Higher doses of ganciclovir may be required in ECMO patients, especially without concurrent CRRT.

This publication has 13 references indexed in Scilit: